The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

Alan K Burnett, Nigel H Russell, Dominic Culligan, Jamie Cavanagh, Jonathan Kell, Keith Wheatley, Andra Virchis, Robert K Hills, Donald Milligan, AML Working Group of the UK National Cancer Research Institute

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)

Abstract

The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a 'Pick a Winner' design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 62-86), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.
Original languageEnglish
Pages (from-to)519-22
Number of pages4
JournalBritish Journal of Haematology
Volume158
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Dive into the research topics of 'The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML'. Together they form a unique fingerprint.

Cite this